Biotechnology Industry Organization (BIO) Urges Senate Committee on Finance Not to Limit Patients’ Access to Therapies

April 13, 2007 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

WASHINGTON--(BUSINESS WIRE)--The Biotechnology Industry Organization (BIO) opposes the Chairman’s Mark to the Medicare Prescription Drug Price Negotiation Act of 2007 (S. 3) which is being considered by the Senate Committee on Finance today.

Twitter
LinkedIn
Facebook
Email
Print

Regulatory